퍼플 바이오텍(PPBT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.44 (-6.80%), 시가총액 $0.00B, PER (주가수익비율) 0.00, 52주 최저~최고 $0.44 ~ $5.02.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or met
퍼플 바이오텍의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
퍼플 바이오텍의 현재 주가는 $1.44 (-6.80%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
퍼플 바이오텍의 시가총액은 약 $0.00B입니다. PER은 0.00입니다.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline incl